A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

NCT00360334 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

235

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: exenatide
DRUG: insulin glargine

Sponsor

AstraZeneca

Collaborators

[object Object]